Eli Lilly and Novo Nordisk Shift Obesity Drug Expansion Focus Beyond the U.S. Market
Claire Weston
Eli Lilly and Novo Nordisk are pivoting GLP-1 weight-loss drug growth from the US to global markets, with Lilly filing for approval in 40 countries; yet price barriers and cultural stigma make the overseas push far harder than the American rollout.
Why are both pharma giants looking beyond America at the same time?
Only 1%–2% of potential patients worldwide currently use GLP-1 drugs — medications that mimic a gut hormone to curb appetite. This means → the rest-of-world market is nearly untouched, with far more room to grow than the increasingly crowded US.
Obesity rates are climbing fastest in low- and middle-income countries, precisely where new weight-loss drugs have almost zero penetration.
In plain terms = the two companies are already fighting over the US slice; the race now is who reaches the remaining 98% first.
How do their global strategies differ?
Lilly is moving aggressively. Its bet centers on Foundayo, an oral drug. The company has filed for regulatory approval in 40 countries and plans large-scale distribution. Executive Ken Custer put it plainly: "It's time to think about global population health."
Novo Nordisk is moving cautiously. Oral Wegovy just launched in the UAE this week — its first market outside the US — while European approval is still underway. International head Emil Kongshoj Larsen stressed: "No half-measures — every country we enter, we commit fully."
This reflects two distinct globalisation logics — Lilly is betting on speed and breadth; Novo is betting on certainty and deep local roots.
Why can't overseas patients afford these drugs?
In Mexico, physician Juan Manuel Esparza Luna reports that many patients cannot afford Wegovy or Zepbound and fall back on less effective older drugs.
He sometimes combines low-dose GLP-1 drugs with older stimulants such as phentermine, or keeps patients on the lowest dose longer — all to achieve one goal: cut costs.
In Hungary, average post-tax monthly pay is under $2,000, and a box of Ozempic without insurance costs roughly $118. Patient advocate Judit Pettko calls it "too expensive for an ordinary family" and urges drugmakers to negotiate subsidies directly with governments.
Can generics break the price deadlock?
Generic versions of semaglutide — the active ingredient in both Wegovy and Ozempic — have already launched this year in India, Canada, and Brazil, bringing cheaper alternatives to market.
This means → brand-name drugmakers face a dilemma: they are opening overseas markets just as generics arrive on their heels, leaving a potentially narrow window for premium-priced originator drugs.
Novo's counter-strategy is to leverage Wegovy's brand recognition to drive demand for the injectable format in markets where the oral version has not yet launched. Put simply = establish the brand name first, then fill in coverage with the full product line.
What else stands between patients and treatment?
Cultural attitudes are a hidden barrier. In India and Pakistan, plump children are seen as healthy and lovable; food traditions run deep. Mumbai obesity specialist Swati Pradhan notes that patients worry about side effects and know little about how the drugs work.
Some Indian women cannot ask family members for money to pay for medication, limiting them to roughly three months of treatment. This signals that weight-loss therapy in these markets is not just a medical question — it is a household financial decision.
Lilly responded to weight-loss stigma with an art installation at the European Obesity Congress in Istanbul — but the distance from "making a statement" to "changing minds" remains vast.
Content is for reference only, not financial advice.